News and Trends 5 Feb 2018
New Antiviral for RSV Lung Infections Shows Promise in Phase IIa
ReViral’s candidate RV521 showed its potential for the treatment of respiratory syncytial virus (RSV) infections by reducing viral load and mucus levels. London-based biotech ReViral discovers and develops antiviral drugs, focusing particularly on the treatment of diseases caused by the respiratory syncytial virus (RSV). The biotech’s candidate, RV521, has undergone a Phase IIa clinical trial during […]